Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc.('Duska') announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S.
Food and Drug Administration's (the...
Interleukin-6 Upregulates Neuronal Adenosine A1 Receptors: Implications for Neuromodulation and Neuroprotectio Knut Biber, A Pinto-Duarte, M C Wittendorp, A M Dolga, C C Fernandes, J Von Frijtag Drabbe Knzel, J N Keijser, R de Vries, A P Ijzerman, J A Ribeiro, U Eisel, A M Sebastio and H W G M Boddeke Interleukin-6 Upregulates Neuronal Adenosine ...
Sagent Pharmaceuticals, Inc Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 7/16/2008 6:50:48 AM More...Sagent Pharmaceuticals, Inc.Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China 5/14/2008 10:41:01 AM More...
Spectrum...
Use Of Adenosine Deaminase For Treating Pulmonary Disease Applicant ENZON PHARMACEUTICALS, INC.BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor(s) BLACKBURN, Michael R.HORAK, IvanSAPRA, PujaKELLEMS, Rodney, E.Title Abstract Provided are methods for treating an adenosinedeaminase-mediated...
ATP shows in vivo hormone-refractory prostate cancer potential MedWire News: Adenosine triphosphate (ATP) reduces the growth of advanced hormone-refractory prostate carcinoma (HRPC) cells in vivo, which may point to a role for the nucleotide in the treatment of prostate cancer say UK investigators...
Wake up and smell the coffee Study finds that caffeine may help prevent MS A good cup of coffee might be just the wake-up call scientists need to stop multiple sclerosis.A new study coauthored by Oklahoma Medical Research Foundation scientist Linda Thompson, Ph.D.,...
Researchers are first to simulate the binding of molecules to a protein , 5:25 PM EST You may not know what it is, but you burn more than your body weight of it every day.Adenosine triphosphate (ATP), a tiny molecule that packs a powerful punch, is the primary energy source for most of your cellular...
Wake up and smell the coffee , 5:25 PM EST A good cup of coffee might be just the wake-up call scientists need to stop multiple sclerosis.A new study coauthored by scientist Linda Thompson, Ph.D., found that mice immunized to develop an MS-like condition were...
Astellas Launches Lexiscan(regadenoson) Injection For Use As A Pharmacologic Stress Agent In Radionuclide 6019 live jobs on pharmiweb.com now -First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease- Deerfield, Ill., June 24, 2008 - Astellas Pharma US, Inc.today announced the commercial availability...
New role for mitochondria could lead to targetted therapies for various diseases In a new study, researchers have found that it is possible for human cells to shift important gene products, called tRNAs, into their own mitochondria, believed to be the power plants of cells - a finding that may help in developing...
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide DEERFIELD, Ill.'Our clinical experience shows that an increasing number of patients are requiring pharmacologic stress agents for MPI studies,' said Gregory Thomas MPI tests, commonly called cardiac stress tests, identify areas of poor...
tRNA import occurs in humans - could lead to targeted therapies Scientists have determined that human cells are able to shift important gene products into their own mitochondria, considered the power plants of cells.The finding could eventually lead to therapies for dozens of diseases.
The gene...
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide -First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease- DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc.today announced the commercial availability of Lexiscan(TM) (regadenoson...
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon PALO ALTO, Calif., June 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.announced today that in conjunction with the commercial launch of Lexiscan(TM) by Astellas Pharma US, Inc., CV Therapeutics has earned a milestone payment of $10...
Astellas Launches Lexiscan (regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myo First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease DEERFIELD, Ill., June 24, 2008 Astellas Pharma US, Inc.today announced the commercial availability of Lexiscan™ (regadenoson)...
Astellas Launches Lexiscan (regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myo First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease DEERFIELD, Ill., June 24, 2008 Astellas Pharma US, Inc.today announced the commercial availability of Lexiscan™ (regadenoson)...
Rolofylline Reduces Congestion and Improves Renal Function for Patients Hospitalised With Acute Heart Failure my personal edition> congestive heart failure > news E-Mail this DGDispatch to a colleague DGDispatch MILAN, Italy -- June 20, 2008 -- Infusions of the adenosine A1 receptor antagonist rolofylline are safe and can provide...
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist _ Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist.
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist - Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma.In March, Inotek received...
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist - Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma.In March, Inotek received...
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist , 1:30 PM EST News source: Business Wire Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of...
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist - Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma.In March, Inotek received...
HemoBioTech Chairman & CEO Arthur Bollon, Ph.D., to Present at the Bio International Convention in San Diego, - Arthur Bollon, Ph.D., chairman & CEO of HemoBioTech, Inc.(OTCBB: HMBT), will present at the 2008 Biotechnology Industry Organization (BIO) International Convention in San Diego, CA tomorrow, June 19, 2008.
Bollon's...
A2a Adenosine Receptor Antagonists The server encountered an internal error and was unable to complete your request.JRun closed connection.
A2a Adenosine Receptor Antagonists.
